India has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics, in the government's latest effort to improve affordability of medicines. The move......
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally. Kyowa Pharmaceutical Industry, drug major Lupin's Japanese subsidiary, has......
India's pharmaceutical industry is expected to see sales and profit growth accelerate in the second half of the year, thanks to a pickup in the pace of US. approvals for new drugs, offsetting any......
India may go to the World Trade Organisation (WTO) if the European Union does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials......
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering......